MX346661B - Stabilized eperisone medical composition, and sustained-release preparation containing same. - Google Patents

Stabilized eperisone medical composition, and sustained-release preparation containing same.

Info

Publication number
MX346661B
MX346661B MX2014004652A MX2014004652A MX346661B MX 346661 B MX346661 B MX 346661B MX 2014004652 A MX2014004652 A MX 2014004652A MX 2014004652 A MX2014004652 A MX 2014004652A MX 346661 B MX346661 B MX 346661B
Authority
MX
Mexico
Prior art keywords
eperisone
stabilized
sustained
preparation containing
medical composition
Prior art date
Application number
MX2014004652A
Other languages
Spanish (es)
Other versions
MX2014004652A (en
Inventor
Lee Chang-Kyoo
Park Sang-Geun
Original Assignee
Navipharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navipharm Co Ltd filed Critical Navipharm Co Ltd
Publication of MX2014004652A publication Critical patent/MX2014004652A/en
Publication of MX346661B publication Critical patent/MX346661B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a stabilized eperisone medical composition, and a sustained-release preparation containing same. More particularly, the present invention relates to a stabilized eperisone medical composition which consists of an eperisone salt and an oxidant as effective ingredients, to thus maintain the chemical stability of the active ingredients during the residence time of drugs in a body as well as the storage of finished products, and also relates to a sustained-release preparation containing the stabilized eperisone which exhibits dual release characteristics of fast- and slow-release because the preparation further includes a release retardant in addition to the eperisone and the oxidant.
MX2014004652A 2011-09-05 2012-03-28 Stabilized eperisone medical composition, and sustained-release preparation containing same. MX346661B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110089687 2011-09-05
KR1020110106388A KR101156054B1 (en) 2011-09-05 2011-10-18 A stable and control-released pharmaceutical composition comprising eperisone
PCT/KR2012/002288 WO2013058450A1 (en) 2011-10-18 2012-03-28 Stabilized eperisone medical composition, and sustained-release preparation containing same

Publications (2)

Publication Number Publication Date
MX2014004652A MX2014004652A (en) 2015-03-05
MX346661B true MX346661B (en) 2017-03-28

Family

ID=48141658

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004652A MX346661B (en) 2011-09-05 2012-03-28 Stabilized eperisone medical composition, and sustained-release preparation containing same.

Country Status (6)

Country Link
JP (1) JP5948648B2 (en)
KR (1) KR101156054B1 (en)
CN (1) CN103889455B (en)
BR (1) BR112014009506B1 (en)
MX (1) MX346661B (en)
WO (1) WO2013058450A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (en) 2010-06-10 2013-02-06 주식회사 네비팜 A composition for treating or preventing osteoporosis and a method of preparing the same
KR101832842B1 (en) * 2012-01-13 2018-02-27 한미약품 주식회사 Pharmaceutical composition with an improved stability comprising eperisone or a pharmaceutically acceptable salt thereof and specific acidifying agent
KR20140118410A (en) * 2013-03-29 2014-10-08 초당약품공업 주식회사 Eperisone pharmaceutical composition enhancing storage and pH stability
KR101497354B1 (en) * 2013-03-29 2015-03-02 초당약품공업 주식회사 Slow release pharmaceutical composition having Eperisone as active ingredient
KR101799321B1 (en) 2016-08-29 2017-11-20 초당약품공업 주식회사 The complex formulation of eperisone sustained release microsphere and aceclofenac
KR101760278B1 (en) 2016-08-29 2017-07-21 초당약품공업 주식회사 Process for preparing sustained release microsphere including eperisone as active ingredient
WO2018044020A1 (en) * 2016-08-29 2018-03-08 초당약품공업 주식회사 Method for preparing eperisone sustained release microsphere, and composite preparation of eperisone sustained release microsphere and aceclofenac
KR102254307B1 (en) 2019-04-03 2021-05-21 위더스제약주식회사 Eperisone-containing pharmaceutical having improved storage-stability
KR102444073B1 (en) * 2020-01-06 2022-09-16 (주)휴온스 Pharmaceutical formulation containing methylergometrine maleate with improved stability and method preparing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0163199B1 (en) * 1990-05-24 1998-12-01 다이도 나오가따 Sustained release suppository
JP3525225B2 (en) * 1992-11-09 2004-05-10 積水化学工業株式会社 Eperisone or tolperisone transdermal absorption tape or patch, and method for producing the same
WO2000024423A1 (en) 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
JP2000143510A (en) * 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd Preparation for external use
AT500144A1 (en) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag TOLPERISON-CONTAINING PHARMACEUTICAL PREPARATION WITH CONTROLLABLE ACTIVE INGREDIENTS FOR ORAL ADMINISTRATION
DE102005014080B4 (en) * 2005-03-21 2007-11-22 Birds Pharma Gmbh Berolina Innovative Research & Development Services Addition salts of tolperisone, process for their preparation, use thereof and medicaments containing them
CN101484142B (en) * 2006-03-24 2013-06-05 奥克思利尤姆国际控股公司 Stabilized compositions containing alkaline labile drugs
AT505225A1 (en) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag Tolperisone and their pharmaceutical acceptable salts and hydrates production for use as active substance in pharmaceutical formulation for drugs, for treatment and therapy of Alzheimer's disease, involves converting methylpropiophenone
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
GEP20135986B (en) * 2009-03-09 2013-12-10 Shashikant Prabhudas Kurani Novel sustained release composition of compounds selected from class of centrally acting muscle relaxants

Also Published As

Publication number Publication date
WO2013058450A1 (en) 2013-04-25
JP2014530250A (en) 2014-11-17
MX2014004652A (en) 2015-03-05
CN103889455B (en) 2017-12-05
KR101156054B1 (en) 2012-06-20
CN103889455A (en) 2014-06-25
BR112014009506B1 (en) 2020-04-07
JP5948648B2 (en) 2016-07-06
BR112014009506A2 (en) 2017-05-09

Similar Documents

Publication Publication Date Title
MX2014004652A (en) Stabilized eperisone medical composition, and sustained-release preparation containing same.
WO2012034055A3 (en) Compounds as c-met kinase inhibitors
MY185139A (en) Substituted imidazopyridazines
MY168413A (en) Amino-substituted imidazopyridazines
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX370852B (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)- 7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof.
MX2013001677A (en) Stable formulations of linaclotide.
MY165149A (en) Use of binders for manufacturing storage stable formulations
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
MX367914B (en) SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a</ i>][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS.
MX344846B (en) Combination of active loaded granules with additional actives.
PH12014502366B1 (en) Injectable formulation
IN2014DN01619A (en)
MX2016004116A (en) Foam formulations and apparatus for delivery.
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
MX2020001404A (en) Dihydrooxadiazinones.
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
MX2013013691A (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient.
WO2013170086A3 (en) Formulations for the delivery of active ingredients
WO2013058527A3 (en) Combined formulation of leukotriene antagonist and epinastine
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
MX2013002446A (en) Substituted tetrahydropyrrolopyrazine derivatives.

Legal Events

Date Code Title Description
FG Grant or registration